Biomea Fusion Inc
BMEA1.285USD
-0.055-4.10%
交易中 （美东）报价延迟15分钟
76.47M总市值
亏损市盈率 TTM
关于 Biomea Fusion Inc 公司
Biomea Fusion, Inc. 是一家临床阶段的生物制药公司。该公司专注于发现和开发口服共价小分子，用于治疗患有代谢疾病和基因定义的癌症的患者。共价小分子是一种合成化合物，可与其靶蛋白形成永久键。该公司正在利用其专有的 FUSION 系统发现、设计和开发一系列共价结合小分子药物，旨在最大限度地为患者带来临床益处。其主要候选产品 BMF-219 旨在成为一种口服、强效且选择性的脑膜炎共价抑制剂，由其 FUSION 系统构建而成。该公司正在开发 BMF-219 用于治疗脑膜炎调节或依赖性疾病，例如 1 型和 2 型糖尿病以及液体和实体肿瘤的亚型。其第二个开发候选产品 BMF-500 是一种 FMS 样酪氨酸激酶 3 (FLT3) 激活突变的共价抑制剂。
Biomea Fusion Inc简介
公司代码BMEA
公司名称Biomea Fusion Inc
上市日期Apr 16, 2021
CEODr. Michael J.M. (Mick) Hitchcock, Ph.D.
员工数量106
证券类型Ordinary Share
年结日Apr 16
公司地址1599 Industrial Road
城市SAN CARLOS
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94070
电话16509809099
网址https://www.biomeafusion.com/
公司代码BMEA
上市日期Apr 16, 2021
CEODr. Michael J.M. (Mick) Hitchcock, Ph.D.
Biomea Fusion Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Rainer M. (Ramses) Erdtmann
Mr. Rainer M. (Ramses) Erdtmann
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director
2.49M
-1.58%
Dr. Eric Aguiar, M.D.
Dr. Eric Aguiar, M.D.
Lead Independent Director
Lead Independent Director
200.00
--
Dr. Michael J.M. (Mick) Hitchcock, Ph.D.
Dr. Michael J.M. (Mick) Hitchcock, Ph.D.
Interim Chief Executive Officer, Director
Interim Chief Executive Officer, Director
--
--
Dr. Juan Pablo Fras
Dr. Juan Pablo Fras
Chief Medical Officer, Head of Diabetes
Chief Medical Officer, Head of Diabetes
--
--
Dr. Elizabeth Faust, Ph.D.
Dr. Elizabeth Faust, Ph.D.
Independent Director
Independent Director
--
--
Ms. Sumita Ray, J.D.
Ms. Sumita Ray, J.D.
Independent Director
Independent Director
--
--
Ms. Meichiel Jennifer Weiss
Ms. Meichiel Jennifer Weiss
Senior Director, Investor Relations and Corporate Development
Senior Director, Investor Relations and Corporate Development
--
--
Ms. Julianne Averill
Ms. Julianne Averill
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Rainer M. (Ramses) Erdtmann
Mr. Rainer M. (Ramses) Erdtmann
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director
2.49M
-1.58%
Dr. Eric Aguiar, M.D.
Dr. Eric Aguiar, M.D.
Lead Independent Director
Lead Independent Director
200.00
--
Dr. Michael J.M. (Mick) Hitchcock, Ph.D.
Dr. Michael J.M. (Mick) Hitchcock, Ph.D.
Interim Chief Executive Officer, Director
Interim Chief Executive Officer, Director
--
--
Dr. Juan Pablo Fras
Dr. Juan Pablo Fras
Chief Medical Officer, Head of Diabetes
Chief Medical Officer, Head of Diabetes
--
--
Dr. Elizabeth Faust, Ph.D.
Dr. Elizabeth Faust, Ph.D.
Independent Director
Independent Director
--
--
Ms. Sumita Ray, J.D.
Ms. Sumita Ray, J.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月19日 周二
更新时间: 8月19日 周二
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
10.45%
Heights Capital Management, Inc.
5.54%
Butler (Thomas Andrew)
4.29%
Erdtmann (Rainer M)
3.60%
Aisling Capital Management LP
2.96%
其他
73.17%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
10.45%
Heights Capital Management, Inc.
5.54%
Butler (Thomas Andrew)
4.29%
Erdtmann (Rainer M)
3.60%
Aisling Capital Management LP
2.96%
其他
73.17%
股东类型
持股股东
占比
Investment Advisor
22.56%
Individual Investor
7.97%
Hedge Fund
6.99%
Investment Advisor/Hedge Fund
5.90%
Research Firm
1.58%
Bank and Trust
0.49%
Venture Capital
0.22%
Family Office
0.06%
其他
54.25%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
269
28.77M
42.50%
+1.53M
2025Q2
269
30.74M
51.66%
-2.41M
2025Q1
286
30.27M
56.89%
-6.92M
2024Q4
291
32.11M
88.62%
-5.43M
2024Q3
283
32.46M
89.61%
-9.72M
2024Q2
276
32.63M
90.57%
-17.02M
2024Q1
262
40.47M
112.52%
-6.23M
2023Q4
249
37.13M
103.84%
-10.53M
2023Q3
227
38.85M
108.96%
-7.82M
2023Q2
225
38.32M
108.02%
-4.44M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
7.24M
12.17%
+1.81M
+33.26%
Jun 30, 2025
Heights Capital Management, Inc.
3.84M
6.45%
+3.84M
--
Jun 30, 2025
Butler (Thomas Andrew)
2.97M
5%
--
--
Mar 31, 2025
Erdtmann (Rainer M)
2.49M
4.19%
-40.00K
-1.58%
Jun 30, 2025
Aisling Capital Management LP
2.05M
3.44%
+1.25M
+156.49%
Jun 30, 2025
The Vanguard Group, Inc.
1.88M
3.16%
+501.63K
+36.40%
Jun 30, 2025
Woodline Partners LP
1.74M
2.93%
+1.50M
+624.05%
Jun 30, 2025
Blue Owl Capital Holdings LP
1.30M
2.18%
+1.30M
--
Jun 30, 2025
Cormorant Asset Management, LP
3.57M
6%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
720.15K
1.21%
-1.24M
-63.32%
Jun 30, 2025
查看更多
持股ETF
更新时间: 10 小时前
更新时间: 10 小时前
机构名称
占比
iShares Micro-Cap ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
SPDR S&P Biotech ETF
0%
iShares Russell 3000 ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.02%
ProShares Ultra Nasdaq Biotechnology
占比0.01%
iShares Biotechnology ETF
占比0.01%
Invesco Nasdaq Biotechnology ETF
占比0.01%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
ProShares Hedge Replication ETF
占比0%
iShares Russell 2000 ETF
占比0%
Proshares Ultra Russell 2000
占比0%
SPDR S&P Biotech ETF
占比0%
iShares Russell 3000 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
